The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products.
No risks detected for 3933 from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$5.09|
|52 Week High||HK$5.00|
|52 Week Low||HK$7.60|
|1 Month Change||0.39%|
|3 Month Change||-10.07%|
|1 Year Change||-24.14%|
|3 Year Change||-6.61%|
|5 Year Change||21.48%|
|Change since IPO||41.00%|
Recent News & Updates
Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
|3933||HK Pharmaceuticals||HK Market|
Return vs Industry: 3933 underperformed the Hong Kong Pharmaceuticals industry which returned -12.1% over the past year.
Return vs Market: 3933 underperformed the Hong Kong Market which returned 6.7% over the past year.
Stable Share Price: 3933 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 3933's weekly volatility (5%) has been stable over the past year.
About the Company
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Intermediate Products, Bulk Medicine, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products.
United Laboratories International Holdings Fundamentals Summary
|3933 fundamental statistics|
Is 3933 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|3933 income statement (TTM)|
|Cost of Revenue||CN¥5.08b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.61|
|Net Profit Margin||12.23%|
How did 3933 perform over the long term?See historical performance and comparison
1.9%Current Dividend Yield
Is United Laboratories International Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 3933 (HK$5.09) is trading below our estimate of fair value (HK$26.17)
Significantly Below Fair Value: 3933 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 3933 is good value based on its PE Ratio (6.9x) compared to the Hong Kong Pharmaceuticals industry average (10x).
PE vs Market: 3933 is good value based on its PE Ratio (6.9x) compared to the Hong Kong market (9.6x).
Price to Earnings Growth Ratio
PEG Ratio: 3933 is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: 3933 is good value based on its PB Ratio (0.8x) compared to the HK Pharmaceuticals industry average (1x).
How is United Laboratories International Holdings forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3933's forecast earnings growth (4.9% per year) is above the savings rate (1.5%).
Earnings vs Market: 3933's earnings (4.9% per year) are forecast to grow slower than the Hong Kong market (17.6% per year).
High Growth Earnings: 3933's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3933's revenue (6.3% per year) is forecast to grow slower than the Hong Kong market (12.4% per year).
High Growth Revenue: 3933's revenue (6.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3933's Return on Equity is forecast to be low in 3 years time (11.5%).
How has United Laboratories International Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3933 has high quality earnings.
Growing Profit Margin: 3933's current net profit margins (12.2%) are higher than last year (6.4%).
Past Earnings Growth Analysis
Earnings Trend: 3933 has become profitable over the past 5 years, growing earnings by 55.5% per year.
Accelerating Growth: 3933's earnings growth over the past year (104.7%) exceeds its 5-year average (55.5% per year).
Earnings vs Industry: 3933 earnings growth over the past year (104.7%) exceeded the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 3933's Return on Equity (12.4%) is considered low.
How is United Laboratories International Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 3933's short term assets (CN¥9.4B) exceed its short term liabilities (CN¥5.6B).
Long Term Liabilities: 3933's short term assets (CN¥9.4B) exceed its long term liabilities (CN¥1.1B).
Debt to Equity History and Analysis
Debt Level: 3933's debt to equity ratio (24.7%) is considered satisfactory.
Reducing Debt: 3933's debt to equity ratio has reduced from 81.8% to 24.7% over the past 5 years.
Debt Coverage: 3933's debt is well covered by operating cash flow (78%).
Interest Coverage: 3933 earns more interest than it pays, so coverage of interest payments is not a concern.
What is United Laboratories International Holdings's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 3933's dividend (1.91%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.24%).
High Dividend: 3933's dividend (1.91%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.8%).
Stability and Growth of Payments
Stable Dividend: 3933's dividend payments have been volatile in the past 10 years.
Growing Dividend: 3933's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (19.6%), 3933's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 3933's dividends in 3 years are forecast to be thoroughly covered by earnings (13.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
United Laboratories International Holdings has no CEO, or we have no data on them.
Experienced Board: 3933's board of directors are seasoned and experienced ( 10.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
The United Laboratories International Holdings Limited's employee growth, exchange listings and data sources
- Name: The United Laboratories International Holdings Limited
- Ticker: 3933
- Exchange: SEHK
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$9.368b
- Shares outstanding: 1.84b
- Website: https://www.tul.com.cn
Number of Employees
- The United Laboratories International Holdings Limited
- 6 Fuk Wang Street
- Yuen Long Industrial Estate
- Yuen Long
- New Territories
- Hong Kong
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 16:23|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.